A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

Completed · Phase 2

Conditions studied: GERD With Erosive Esophagitis

In brief

The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and 75 mg). The secondary objectives are to compare the efficacy between the three doses of AZD0865 and esomeprazole 40 mg and to evaluate the safety and tolerability of AZD0865.

Key facts

Study ID

NCT00206245

Run by

AstraZeneca

People needed

1400

Starts

2004-05-01

Expected to finish

2005-03-01

Last updated by the study team

2013-01-04

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Identification of their main symptom as heartburn defined as a burning feeling behind the breastbone.
• Have at least a 6-month history of heartburn and at least 4 days of episodes of heartburn with at least overall moderate intensity during the last 7 days prior to visit 1.
• Erosive esophagitis according to LA classification Grade A, B, C or D, at the visit 1 endoscopy.
• Have provided Informed consent.

You may not qualify if…

• Subjects with current or historical evidence of the following conditions are excluded from the study:
• Esophageal stricture.
• Primary esophageal motility disorder(s), i.e. diffuse esophageal spasm, achalasia.
• Systemic Sclerosis (scleroderma).
• Irritable Bowel Syndrome (IBS), i.e. upper abdominal discomfort or pain that in the opinion of the Investigator is likely to be due to IBS or fulfilling two or more of the criteria: relieved by defecation, associated with change in frequency of stools, associated with change in form (appearance) of stools.
• Inflammatory bowel disease.
• Zollinger-Ellison syndrome.
• Gastric ulcer, duodenal ulcer or duodenal erosions within the last 3 months
• Subjects with i) history of significant or ii) current significant or unstable:
• Cardiovascular diseases or cardiac chest pain.
• Cerebrovascular diseases, such as cerebral ischemia, infarction, haemorrhage, or embolus.
• Diabetes mellitus. Stable diabetes controlled on diet, oral agents or insulin is acceptable.
• Pulmonary, renal, pancreatic or liver diseases or any other serious disease as judged by the investigator to interfere with the evaluation of the current study.
• Malignant disease (except for minor superficial skin disease).
• Generalised bleeding disorders.

Where it is running

• Research Site — Huntsville, Alabama, United States
• Research Site — Tucson, Arizona, United States
• Research Site — North Little Rock, Arkansas, United States
• Research Site — Anaheim, California, United States
• Research Site — Cypress, California, United States
• Research Site — Garden Grove, California, United States
• Research Site — Lancaster, California, United States
• Research Site — Los Angeles, California, United States
• Research Site — Mission Hills, California, United States
• Research Site — Orange, California, United States
• Research Site — Rancho Cucamonga, California, United States
• Research Site — San Diego, California, United States
• Research Site — Torrance, California, United States
• Research Site — Wheat Ridge, Colorado, United States
• Research Site — Manchester, Connecticut, United States
• Research Site — Davie, Florida, United States
• Research Site — Gainesville, Florida, United States
• Research Site — Hialeah, Florida, United States
• Research Site — Jacksonville, Florida, United States
• Research Site — Jupiter, Florida, United States
• Research Site — Miami, Florida, United States
• Research Site — Ocoee, Florida, United States
• Research Site — West Palm Beach, Florida, United States
• Research Site — Zephyrhills, Florida, United States
• Research Site — Alabaster, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.